Proteo Inc (PTEO) 0.0700 $PTEO Ischemia Reperfusion

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Proteo Inc (PTEO) 0.0700 $PTEO

Ischemia Reperfusion Injury Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s73kf/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Reperfusion Injury Overview - Therapeutics Development - Pipeline Products for Ischemia Reperfusion Injury - Overview - Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis - Ischemia Reperfusion Injury - Therapeutics under Development by Companies - Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes - Ischemia Reperfusion Injury - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia Reperfusion Injury - Products under Development by Companies - Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes - Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development - Alligator Bioscience AB - Angion Biomedica Corp. - Antipodean Pharmaceuticals, Inc. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Curatis Pharma GmbH - Enteris BioPharma, Inc. - Erimos Pharmaceuticals, LLC - Gilead Sciences, Inc. - Ischemix - Kowa Company, Ltd. - LG Life Science LTD. - Omeros Corporation - Opsona Therapeutics Limited - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. (Inactive) - Prothix BV - Trophos SA - Zealand Pharma A/S For more information visit http://www.researchandmarkets.com/research/9s73kf/ischemia
GILD: 84.25 (-0.61), OMER: 11.56 (+0.33)

Global Pulmonary Arterial Hypertension Pipeline Report H2 2015
M2 - Thu Dec 10, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7nnftw/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bial - Portela & Ca, S.A. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Insmed Incorporated - Lacer, S.A. - LTT Bio-Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - miRagen Therapeutics, Inc. - Nippon Shinyaku Co., Ltd. - Novartis AG - Peloton Therapeutics, Inc. - PharmaIN Corporation - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Pulmokine, Inc. - Reata Pharmaceuticals, Inc. - Respira Therapeutics, Inc. - Sagene Pharmaceuticals, Inc. - Silence Therapeutics Plc - Sinoxa Pharma GmbH - SteadyMed Therapeutics, Inc. - Suda Ltd - Toray Industries, Inc. For more information visit http://www.researchandmarkets.com/research/7nnftw/pulmonary
CYTK: 9.77 (+0.11), INSM: 10.16 (+0.07), PSTI: 1.33 (-0.02), LLY: 79.23 (+0.28), CLSN: 1.30 (+0.02), ASND: 13.39 (+0.36), GILD: 84.25 (-0.61), ARNA: 1.61 (-0.05), NVS: 81.60 (-1.11)

Worldwide Esophageal Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 07, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kppx92/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adaptimmune Limited - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Genmab A/S - Glycotope GmbH - Hutchison MediPharma Limited - Ignyta, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MacroGenics, Inc. - Mebiopharm Co., Ltd. - MedImmune, LLC - Novartis AG - Omeros Corporation - Pfizer Inc. - Precision Biologics, Inc. - Proteo, Inc. - Puma Biotechnology, Inc. - Shionogi & Co., Ltd. - Spectrum Pharmaceuticals, Inc. - Symphogen A/S - Virocan Therapeutics Private Limited - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kp...eal_cancer
MGNX: 26.52 (-0.67), CLRB: 3.35 (-0.10), ADXS: 7.98 (-0.19), PFE: 35.83 (+0.26), CLDX: 4.51 (-0.08), ARQL: 1.73 (-0.12), AMGN: 154.31 (+0.03), SPPI: 6.74 (+0.05), OMER: 11.56 (+0.33), JNJ: 122.98 (+1.69), RXDX: 5.58 (-0.16), AZN: 30.19 (-0.23), AVEO: 0.94 (unch), PBYI: 28.34 (-1.88), NVS: 81.60 (-1.11), KPTI: 7.02 (-0.17), ARRY: 3.61 (-0.02), CELGZ: 1.40 (unch)

Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 84.25 (-0.61), OMER: 11.56 (+0.33)

Lung Transplantation Therapeutics Pipeline Review, H1 2015 - 3 Companies & 7 Drug Profiles
M2 - Tue Jul 28, 8:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dfxfn5/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kamada Ltd. - Proteo, Inc. - Quark Pharmaceuticals, Inc. Drug Profiles - alpha-1 proteinase inhibitor (human) - Elafin - FX-06 - R-503 - R-801 - Recombinant Human Follistatin - RNAi Oligonucleotide for Lung Diseases For more information visit http://www.researchandmarkets.com/research/dfxfn5/lung
KMDA: 3.63 (-0.02)

Pulmonary Hypertension - Pipeline Review, H1 2015
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7z25d/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Ikaria Inc. - Insmed Incorporated - Ironwood Pharmaceuticals, Inc. - Lacer, S.A. - Longevity Biotech, Inc - LTT Bio-Pharma Co., Ltd. - Novartis AG - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Reata Pharmaceuticals, Inc. - RegeneRx Biopharmaceuticals, Inc. - Therametrics holding AG - Toray Industries, Inc. - United Therapeutics Corporation - Vectura Group plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/n7z25d/pulmonary
CYTK: 9.77 (+0.11), INSM: 10.16 (+0.07), PSTI: 1.33 (-0.02), UTHR: 107.85 (-1.04), CLDN: 1.15 (-0.02), LLY: 79.23 (+0.28), CLSN: 1.30 (+0.02), ASND: 13.39 (+0.36), IRWD: 12.99 (-0.20), GILD: 84.25 (-0.61), ARNA: 1.61 (-0.05), NVS: 81.60 (-1.11)

Proteo, Inc. / Proteo Biotech AG: Elafin Combined with Cyclosporine Promises to Overcome Limitations of Cyclosporine for Preventing Irreversible Damage to Transplanted Organs.
BusinessWire - Thu Mar 12, 8:00AM CDT
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced the publication of new results from a group of researchers lead by Mark Nicolls at the Stanford School of Medicine which demonstrate that Elafin and cyclosporine A act synergistically to prevent the development of irreversible damage to transplanted lung tissue in an animal model.

Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 11.56 (+0.33)

Proteo Biotech AG Expands Management Board
BusinessWire - Fri Dec 05, 4:00AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the company strengthens its Management Board. The Supervisory Board of Proteo Biotech AG has appointed Dr. Juergen Paal as a new member of the company's Management Board, effective from Dec 1st, 2014. In this leadership role as Proteo Biotech AG's new Chief Operating Officer, he will be responsible for Proteo's clinical development program, product launch preparation, business development and partnering initiatives.

Proteo, Inc. / Proteo Biotech AG: Final Analysis of the Phase II Clinical Study on Elafin in Coronary Artery Bypass Surgery Completed
BusinessWire - Fri Nov 21, 5:30AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the NHS Lothian's Edinburgh Heart Centre has completed final analysis of data from the investigator initiated Phase II clinical trial (EMPIRE study) with Proteo's drug candidate Elafin for prevention of myocardial injury after coronary artery bypass surgery (CABG). The EMPIRE study was designed as a randomized, double-blinded and placebo-controlled study on 87 patients to investigate the therapeutic potential of a single preoperative Elafin dose on postoperative myocardial injury. This was measured by troponin I plasma concentration which is released by damaged heart muscle cells and its plasma concentration correlates with overall damage of the heart muscle. It was assumed that this treatment would lower the troponin I release over 48 hours. Publication of the EMPIRE study results is planned in a peer reviewed journal.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 61

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 455

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Shaquille O'Neal Empowers Young Leaders with New Scholarship

Updated Category News Views 743

Shaquille O'Neal Champions the Future of Entrepreneurship Full scholarships, elite mentorship, and real-world learning experiences are now within reach for aspiring creators and entrepreneurs, thanks to a groundbreaking initiative launched by Campus, a modern two-year college committed to nurturing the next generation of leaders. This new scholarship program, backed by...

Continue Reading
Investors Take Action: Class Action Lawsuits on the Rise

Updated Category News Views 146

Protecting Your Investments: Class Action Overview Investing in public companies often comes with risks, and sometimes those risks manifest as legal issues. Recently, class action lawsuits have sprung up involving several well-known companies. These lawsuits present opportunities for investors to raise their voices against corporate misconduct and reclaim lost...

Continue Reading
Top Strategies from DealerFire to Enhance Website Engagement

Updated Category News Views 171

Effective Strategies to Reduce Dealership Website Bounce Rates Transforming website visitors into clients is essential for dealerships, and DealerFire offers insightful strategies to enhance website performance effectively. Boosting Page Load Speed The Importance of Speed Website speed plays a critical role in keeping visitors on the site. DealerFire stresses the need to...

Continue Reading
Lassila & Tikanoja's Annual General Meeting Announcement

Updated Category News Views 115

Notice of the Annual General Meeting Lassila & Tikanoja plc has issued a notice regarding the upcoming Annual General Meeting. This meeting serves as an important gathering for shareholders to discuss significant matters concerning the company's future. Meeting Details The Annual General Meeting will take place on Thursday, March 27, 2025, at 4:00 PM, with registration...

Continue Reading
Soapy Joe's Expands Its Reach with 25th Car Wash Location

Updated Category News Views 490

Soapy Joe's Expands Its Reach with 25th Car Wash Location Soapy Joe's Car Wash, a family-owned favorite in the San Diego area, is thrilled to announce the arrival of its 25th location in the community. This new car wash is positioned to provide not only top-notch car cleaning services but also a unique, enjoyable experience for local residents. Grand Opening Celebration...

Continue Reading